Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on ...

Rhythm Pharmaceuticals (RYTM) announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek 2025, held last week ...

Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...

If claiming for a Documented Loss Cash Payment for the AT&T 1 Data Incident and a Documented Loss Cash Payment for the AT&T 2 ...

Abstract available on ASH websiteSAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” ...

VANCOUVER, BC / ACCESS Newswire / November 12, 2025 / American Critical Minerals Corp. (“American Critical Minerals” or the “Company“) (CSE:KCLI)(OTCQB:APCOF)(FRANKFURT:2P30) is pleased to announce ...

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking ...

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving ...